JIC
MACK

Joel Isaacson & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Joel Isaacson & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-928
Closed -$49K – 508
2013
Q2 		$49K Buy
+928
New +$40.7K 0.02% 227

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Joel Isaacson & Co's MACK Position: Q3 2013 in Review

Joel Isaacson & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2013, closing a stake of 928 shares — an estimated $49K sold.

Joel Isaacson & Co first reported a position in MACK in Q2 2013 and held it in 1 quarter. The position peaked at $49K in Q2 2013. 95 funds tracked by Wall St. Rank hold MACK as of Q3 2013.

  • Joel Isaacson & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Joel Isaacson & Co sold 928 Merrimack Pharmaceuticals, Inc. shares in Q3 2013, an estimated $49K.
  • Joel Isaacson & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Joel Isaacson & Co's Merrimack Pharmaceuticals, Inc. position peaked at $49K in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2013.

Based on Joel Isaacson & Co's 13F filing for Q3 2013, filed 26 Feb 2014.